Innocoll Technologies

Innocoll is a specialty pharmaceutical company focused on the development and commercialization of collagen-based drug delivery products. Utilizing its proprietary CollaRx technology platform, the company creates biodegradable surgical implants and topical films designed to provide targeted, sustained release of therapeutic agents. Its lead product, XARACCOLL (bupivacaine collagen implant), is FDA-approved for postsurgical analgesia following open inguinal hernia repair. Innocoll maintains a vertically integrated structure with specialized GMP manufacturing facilities in Germany and corporate headquarters in Ireland. The company was acquired by Gurnet Point Capital in 2017 and continues to advance its pipeline in pain management and wound care.